LogicBio Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch LOGC and buy or sell other stocks, ETFs, and their options commission-free!About LOGC
LogicBio develops gene therapy vectors for previously incurable genetic and infectious diseases. It is committed to delivering genetic medicine to pediatric patients with rare diseases.
CEOFrédéric Chéreau, MBA
CEOFrédéric Chéreau, MBA
Employees—
Employees—
HeadquartersLexington, Massachusetts
HeadquartersLexington, Massachusetts
Founded2014
Founded2014
Employees—
Employees—
LOGC Key Statistics
Market cap68.23M
Market cap68.23M
Price-Earnings ratio-2.57
Price-Earnings ratio-2.57
Dividend yield—
Dividend yield—
Average volume148.34K
Average volume148.34K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$3.53
52 Week high$3.53
52 Week low$0.2573
52 Week low$0.2573
Stock Snapshot
With a market cap of 68.23M, LogicBio Therapeutics(LOGC) trades at $2.07. The stock has a price-to-earnings ratio of -2.57.
During the trading day, LogicBio Therapeutics(LOGC) stock saw an opening price of —, a peak of —, and a bottom of —.
Trading volume for LogicBio Therapeutics(LOGC) stock has reached 0, versus its average volume of 148.34K.
Over the past 52 weeks, LogicBio Therapeutics(LOGC) stock has traded between a high of $3.53 and a low of $0.26.
Over the past 52 weeks, LogicBio Therapeutics(LOGC) stock has traded between a high of $3.53 and a low of $0.26.
People also own
Based on the portfolios of people who own LOGC. This list is generated using Robinhood data, and it’s not a recommendation.